Biocompatibles International plc Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Farnham United Kingdom (1984)
Status: Acquired by BTG (2010) → now Boston Scientific Corporation (2018)

Organization Overview

First Clinical Trial
2008
NCT00877071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biocompatibles UK Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 13